How Do Viral Vectors Deliver Genes in Therapy?
Researchers use viral vectors, particularly adeno-associated viruses, as specialized biological delivery vehicles to transport functional genetic material directly into patient cells. By replacing native viral genes responsible for replication with therapeutic expression cassettes, scientists leverage the natural infection mechanisms of viruses while eliminating pathogenicity. This overview explores how these engineered vectors bind, enter, navigate the intracellular space, and establish persistent gene expression to treat genetic disorders.
Engineering Adeno-Associated Viruses for Therapy
Adeno-associated virus (AAV) is a small, non-enveloped parvovirus possessing a single-stranded DNA genome of approximately 4.7 kilobases. Naturally, the wild-type genome is flanked by two inverted terminal repeats (ITRs) and contains two genes: rep (encoding proteins required for replication and site-specific integration) and cap (encoding structural capsid proteins and assembly-activating proteins).
To construct a therapeutic recombinant AAV (rAAV) vector:
- Genome Disarming: The native rep and cap genes are excised. Only the cis-acting flanking ITRs are retained, which provide the packaging and priming signals necessary for genome replication and encapsidation.
- Payload Insertion: A custom therapeutic expression cassette is inserted between the ITRs. This cassette consists of a promoter (cell-type specific or ubiquitous), the transgene of interest, and a polyadenylation sequence. The maximum packaging capacity is constrained near 4.7 to 5.0 kilobases.
- Packaging in Production Cells: Recombinant viral capsids are assembled in producer cells (e.g., HEK293 or insect cells) by supplying rep, cap, and essential helper virus genes (derived from adenovirus or herpesvirus) in trans via plasmids or baculoviral delivery.
Cellular Uptake and Receptor Recognition
The primary determinant of tissue tropism—which cell types the vector preferentially transduces—is the capsid protein shell encoded by the specific AAV serotype or engineered capsid variant.
- Primary Attachment: Capsid surface loops interact with cell-surface glycans, including heparan sulfate proteoglycans (AAV2), sialic acids (AAV4, AAV5), or galactose residues (AAV9).
- Coreceptor Engagement: Following initial attachment, the capsid engages secondary protein coreceptors, such as the universal AAV receptor (AAVR), integrins, or fibroblast growth factor receptors (FGFRs), triggering receptor-mediated endocytosis.
Endosomal Trafficking and Nuclear Entry
Once internalized within endocytic vesicles, the vector navigates through the intracellular environment to deliver its genetic payload to the nucleus:
- Endosomal Acidification and Maturation: Endosomes progress from early to late compartments, accompanied by a drop in luminal pH. The acidic environment triggers conformational rearrangements in the AAV capsid, exposing the VP1/VP2 unique domains containing phospholipase A2 (\(PLA_2\)) activity.
- Endosomal Escape: The active \(PLA_2\) domain facilitates the breach or permeabilization of the endosomal membrane, allowing the intact or partially disassembled capsid to escape into the cytosol.
- Nuclear Translocation: The viral capsid is transported along the microtubule network to the nuclear envelope, entering the nucleus via nuclear pore complexes intact or uncoating at the nuclear pore.
Gene Expression and Genome Persistence
Upon nuclear entry, the single-stranded DNA (ssDNA) genome must be converted into a transcriptionally active double-stranded template:
- Second-Strand Synthesis: Host cellular DNA polymerases synthesize the complementary strand using the hairpin-structured ITR as a primer. Alternatively, self-complementary AAV (scAAV) vectors can be engineered with a mutated ITR that bypasses this rate-limiting step by folding into a double-stranded hairpin upon release.
- Episomal Concatemerization: The double-stranded genomes persist primarily as circular or linear episomes (extrachromosomal concatemers). Because wild-type rep is absent, chromosomal integration occurs at extremely low frequencies, drastically reducing the risk of insertional mutagenesis.
- Transcriptional Activation: Host RNA polymerase II binds the recombinant promoter to initiate transcription of the transgene, resulting in stable, long-term therapeutic protein expression in post-mitotic or slowly dividing target tissues such as neurons, cardiomyocytes, and hepatocytes.